Email Alert RSS
Volume 11 Issue 3
May  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(3): 276-282
Jiang-hong DENG, Cai-feng LI. Improving the Acknowledge of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 276-282. doi: 10.3969/j.issn.1674-9081.20200069
Citation: Jiang-hong DENG, Cai-feng LI. Improving the Acknowledge of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 276-282. doi: 10.3969/j.issn.1674-9081.20200069
shu

Improving the Acknowledge of Childhood-onset Systemic Lupus Erythematosus

doi: 10.3969/j.issn.1674-9081.20200069

  • Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China

More Information
  • Corresponding author: LI Cai-feng   Tel: 86-10-59616306/59616316,E-mail:caifeng_li@yeah.net
  • Received Date: 2020-03-10
  • Publish Date: 2020-05-30
    Abstract
  • Childhood-onset systemic lupus erythematosus (cSLE), which refers to SLE before the age of 18, is the second systemic connective tissue disease in children. Compared with adults, cSLE has its own characteristics in epidemiology, clinical presentation, and treatment. In recent years, with the rapid development of human genomics and molecular biology, the understanding of the disease has been updated. This paper reviewed recent progress in the etiology, manifestation, and treatment of cSLE, so as to better understand this disease and guide clinical practice.
    • FullText(HTML)
  • loading
    • References(52)
  • [1] Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood[J]. Arthritis Care Res (Hoboken), 2012:64:1787-1793. doi:  10.1002/acr.21757
    [2] Livingston B,Bonner A,Pope J.Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus:a meta-analysis[J].Lupus,2011,20:1345-1355. doi:  10.1177/0961203311416694
    [3] Tektonidou MG, Lewandowski LB, Hu J, et al. Survival in adults and children with systemic lupus erythematosus:a systematic review and Bayesian meta-analysis of studies from 1950 to 2016[J]. Ann Rheum Dis, 2017,76:2009-2016. doi:  10.1136/annrheumdis-2017-211663
    [4] Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2010, 6:538-546. doi:  10.1038/nrrheum.2010.121
    [5] Pineles D, Valente A, Warren B, et al. Worldwide incid-ence and prevalence of pediatric onset systemic lupus erythematosus[J]. Lupus, 2011,20:1187-1192. doi:  10.1177/0961203311412096
    [6] Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus[J]. Best Prac Res Clin Rheum,2018, 32:188-205. doi:  10.1016/j.berh.2018.09.004
    [7] Cattalini M, Soliani M, Caparello MC, et al. Sex differences in pediatric rheumatology[J]. Clin Rev Allergy Immunol, 2019,56:293-307. doi:  10.1007/s12016-017-8642-3
    [8] Mina R, Brunner HI. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?[J]. Rheum Dis Clin North Am,2010,36:53-80. doi:  10.1016/j.rdc.2009.12.012
    [9] Watson L, Leone V, Pilkington C, et al.Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort[J].Arthritis Rheum, 2012, 64:2356-2365. doi:  10.1002/art.34410
    [10] Rees F, Doherty M, Grainge MJ, et al. Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012[J]. Rheumatology (Oxford), 2016, 55:854-860. doi:  10.1093/rheumatology/kev424
    [11] Harry O, Yasin S, Brunner HI. Childhood-Onset Systemic Lupus Erythematosus:A Review and Update[J]. J Pediatr,2018,196:22-30. doi:  10.1016/j.jpeds.2018.01.045
    [12] Rahman A, Isenberg DA. Systemic lupus erythematosus[J]. N Engl J Med, 2008, 358:929-939. doi:  10.1056/NEJMra071297
    [13] Kwon Y, Chun S, Kim K, et al. Update on the Genetics of Systemic Lupus Erythematosus:Genome-Wide Association Studies and Beyond[J]. Cells,2019,8:1180. doi:  10.3390/cells8101180
    [14] Webber D, Cao J, Dominguez D, et al. Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE[J]. Rheumatology (Oxford), 2020,59:90-98. doi:  10.1093/rheumatology/kez220
    [15] Omarjee O, Picard C, Frachette C, et al. Monogenic Lupus:dissecting heterogeneity[J]. Autoimmun Rev,2019,18:102361. doi:  10.1016/j.autrev.2019.102361
    [16] Wu YL, Brookshire BP, Verani RR, et al. Clinical presentations and molecular basis of complement C1r deficiency in a male African-American patient with systemic lupus erythematosus[J]. Lupus, 2011, 20:1126-1134. doi:  10.1177/0961203311404914
    [17] Crow YJ, Chase DS, Schmidt JL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1[J].Am J Med Genet A, 2015, 167A:296-312. https://www.escholar.manchester.ac.uk/uk-ac-man-scw:263148
    [18] Butbul AY, Mandel H, Hersh EA, et al. Prolidase deficiency associated with systemic lupus erythematosus (SLE):single site experience and literature review[J].Pediatr Rheumatol Online J, 2012,10:18. doi:  10.1186/1546-0096-10-18
    [19] Ellyard JI, Jerjen R, Martin JL, et al. Identification of a pathogenic variant in TREX1 in early-onset cerebral systemic lupus erythematosus by Whole-exome sequencing[J]. Arthritis Rheumatol, 2014, 66:3382-3386. doi:  10.1002/art.38824
    [20] Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE)-pathophysiological concepts and treatment options[J].Best Pract Res Clin Rheumatol, 2017, 31:488-504. doi:  10.1016/j.berh.2018.02.001
    [21] Hakkim A, Fürnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis[J]. Proc Natl Acad Sci U S A,2010,107:9813-9818. doi:  10.1073/pnas.0909927107
    [22] Wilkinson MGL, Rosser EC. B cells as a therapeutic target in paediatric rheumatic disease[J]. Front Immunol, 2019,10:214. doi:  10.3389/fimmu.2019.00214
    [23] Edelbauer M, Kshirsagar S, Riedl M, et al. Activity of childhood lupus nephritis is linked to altered T cell and cytokine homeostasis[J].J Clin Immunol, 2012, 32:477-487. doi:  10.1007/s10875-011-9637-0
    [24] Crispin JC, Hedrich CM, Suárez-Fueyo A, et al. SLE-associated defects promote altered T cell function[J]. Crit Rev Immunol, 2017, 37:39-58. doi:  10.1615/CritRevImmunol.2018025213
    [25] Menon M, Blair PA, Isenberg DA, et al. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus[J].Immunity, 2016, 44:683-697. doi:  10.1016/j.immuni.2016.02.012
    [26] Knight JS,Kaplan MJ. Lupus neutrophils:'NET' gain in understanding lupus pathogenesis[J]. Curr Opin Rheumatol,2012,24:441-450. doi:  10.1097/BOR.0b013e3283546703
    [27] Kaul A, Gordon C, Crow MK,et al. Systemic lupus erythematosus[J]. Nat Rev,2016,2:1-21. https://www.cdc.gov/lupus/facts/detailed.html
    [28] Samanta M, Nandi M, Mondal R, et al. Childhood lupus nephritis:12 years of experience from a developing country's perspective[J]. Eur J Rheumatol, 2017, 4:178-183. doi:  10.5152/eurjrheum.2017.16117
    [29] Al-Mayouf SM, AlAmeer A, Alfattani A, et al. Outcome of childhood lupus nephritis in Saudi children[J].Saudi J Kidney Dis Transpl, 2017,28:1015-1020. doi:  10.4103/1319-2442.215142
    [30] Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis:the SHARE initiative[J]. Ann Rheum Dis,2017,76:1965-1973. doi:  10.1136/annrheumdis-2017-211898
    [31] Ambrose N, Morgan TA, Galloway J, et al. Differences in disease phenotype and severity in SLE across age groups[J].Lupus, 2016, 25:1542-1550. doi:  10.1177/0961203316644333
    [32] Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhoodonset systemic lupus erythematosus:the SHARE initiative[J].Ann Rheum Dis, 2017,76:1788-1796. doi:  10.1136/annrheumdis-2016-210960
    [33] Vega-Fernandez P, Vanderburgh White S, Zelko F, et al. Cognitive Performance scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood Onset systemic lupus erythematosus[J]. Arthritis Care Res, 2015,67:1119-1127. doi:  10.1002/acr.22571
    [34] Abdwani R, Abdalla E, Al-Zakwani I.Unique characteris-tics of prepubertal onset systemic lupus erythematosus[J]. Int J Pediatr, 2019, 9537065. http://downloads.hindawi.com/journals/ijpedi/2019/9537065.pdf
    [35] Gomes RC, Silva MF, Kozu K, et al.Features of 847 childhood-onset systemic lupus erythematosus patients in three age groups at diagnosis:a Brazilian Multicenter Study[J]. Arthritis Care Res (Hoboken),2016, 68:1736-1741. doi:  10.1002/acr.22881
    [36] Groot N, Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of pediatric antiphospholipid syndrome:the SHARE initiative[J]. Ann Rheum Dis,2017,76:1637-1641. doi:  10.1136/annrheumdis-2016-211001
    [37] Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythe-matosus[J]. Arthritis Rheum, 2019,71:1400-1412. doi:  10.1002/art.40930
    [38] Groot N, Shaikhani D, Teng YKO, et al. Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus[J]. Arthritis Rheum, 2019, 71:290-301. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=192e6d7bbf75f7f0220c1d25afa028c0
    [39] Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus:Update on clinical presentation, pathophysiology and treatment options[J]. Clin Immun, 2019, 209:1-12. https://www.ncbi.nlm.nih.gov/pubmed/31678365
    [40] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78:736-745. doi:  10.1136/annrheumdis-2019-215089
    [41] Morgan TA, Watson L, McCann LJ,et al. Children and adolescents with SLE:not just little adults[J]. Lupus, 2013, 22:1309-1319. doi:  10.1177/0961203313502863
    [42] Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus[J]. Arthritis Care Res,2012,64:375-383. doi:  10.1002/acr.21558
    [43] Deng J, Chalhoub NE, Sherwin CM, et al. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2019, 49:251-259. doi:  10.1016/j.semarthrit.2019.03.010
    [44] Michaud M, Catros F, Ancellin S, et al. Treatment of systemic lupus erythematosus:don't forget hydroxychloroquine[J]. Ann Rheum Dis, 2019.doi:10.1136/annrheumdis-2019-215799.[Epub ahead of print].
    [45] Marmmor MF, Kellner U, Lai TY, et al. Recommendations on screening for Chloroquine and hydroxychloroquine retinopathy (2016 Revision)[J]. Ophthalmology,2016,123:1386-1394. doi:  10.1016/j.ophtha.2016.01.058
    [46] Tian SY, Silverman ED, Pullenayegum E, et al. Com-parative effectiveness of mycophenolate mofetil for the treatment of juvenile-onset proliferative lupus nephritis[J].Arthritis Care Res (Hoboken),2017, 69:1887-1894. doi:  10.1002/acr.23215
    [47] Chan VS, Tsang HH, Tam RC, et al. B-cell-targeted therapies in systemic lupus erythematosus[J]. Cell Mol Immunol, 2013,10:133-142. doi:  10.1038/cmi.2012.64
    [48] Peterknecht E, Keasey MP, Beresford MW. The effective-ness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE):a systematic review[J]. Lupus, 2018,27:2135-2145. doi:  10.1177/0961203318804879
    [49] 贺成美,张奉春.贝利木单克隆抗体:治疗系统性红斑狼疮的新型靶向药物[J].协和医学杂志,2020,11:130-134. http://oldmed.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_xhyx202002003
    [50] Brunner HI, Martini A, Lovell DJ, et al. Clinical trials in children and adolescents with systemic lupus erythematosus:methodological aspects, regulatory landscape and future opportunities[J].2019,78:162-170.
    [51] Ruperto N, Abud-Medonza C, Viola DO, et al. The PLUTO study:Intravenous Belimumab in Children with Systemic Lupus Erythematosus[C]. 2019 EULAR Annual European Congress of Rheumatology, 2019.
    [52] Rodriguez-Smith J,Brunner HI. Update on the treatment and outcome of systemic lupus erythematous in children[J]. Curr Opin Rheumatol,2019, 31:464-470. doi:  10.1097/BOR.0000000000000621
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (312) PDF downloads(132) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return